A5055944578- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Aortic Disease and Treatment Approaches
- Cardiac pacing and defibrillation studies
- Cardiac Imaging and Diagnostics
- Cardiovascular Function and Risk Factors
- Cardiac, Anesthesia and Surgical Outcomes
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Congenital Heart Disease Studies
- Coronary Interventions and Diagnostics
- Cardiac Structural Anomalies and Repair
- Pulmonary Hypertension Research and Treatments
- Cardiovascular and Diving-Related Complications
- Traumatic Brain Injury and Neurovascular Disturbances
- Heart Failure Treatment and Management
- Acute Myocardial Infarction Research
- Cardiomyopathy and Myosin Studies
- Trauma and Emergency Care Studies
- Cardiac electrophysiology and arrhythmias
- Cardiac and Coronary Surgery Techniques
- Venous Thromboembolism Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Cerebrospinal fluid and hydrocephalus
- Orthopaedic implants and arthroplasty
Waikato Hospital
2014-2025
Waikato District Health Board
2014-2023
University of British Columbia
2006-2022
Yale University
2022
University of Waikato
2019
Monash Health
2015
Monash University
2015
Hy-Line (United States)
2009
Providence Health Care
2008
St. Paul's Hospital
2006-2008
Background— Percutaneous aortic valve replacement represents an endovascular alternative to conventional open heart surgery without the need for sternotomy, aortotomy, or cardiopulmonary bypass. Methods and Results— Transcatheter implantation of a balloon-expandable stent using femoral arterial approach was attempted in 50 symptomatic patients with severe stenosis whom there consensus that risks were very high. Valve successful 86% patients. Intraprocedural mortality 2%. Discharge home...
Background— Percutaneous aortic valve implantation by an antegrade transvenous approach has been described but is problematic. Retrograde prosthetic via the femoral artery potential advantages. arterial and initial experience reported. Methods Results— The prosthesis constructed from a stainless steel stent with attached trileaflet equine pericardial fabric cuff. After routine balloon valvuloplasty, 22F or 24F sheath advanced to aorta. A steerable, deflectable catheter facilitates...
Aortic valve replacement with cardiopulmonary bypass is currently the treatment of choice for symptomatic aortic stenosis but carries a significant risk morbidity and mortality, particularly in patients comorbidities. Recently, percutaneous transfemoral implantation has been proposed as viable alternative selected patients. We describe our experience new, minimally invasive, catheter-based approach to via left ventricular apical puncture without or sternotomy.A anterolateral intercostal...
Polymer-free drug-coated stents provide superior clinical outcomes to bare-metal in patients at high bleeding risk who undergo percutaneous coronary intervention (PCI) and are treated with 1 month of dual antiplatelet therapy. Data on the use polymer-based drug-eluting stents, as compared polymer-free such limited.In an international, randomized, single-blind trial, we zotarolimus-eluting umirolimus-coated risk. After PCI, were therapy, followed by single The primary outcome was a safety...
The purpose of this study was to prospectively evaluate the safety and clinical performance CoreValve Evolut R transcatheter aortic valve replacement (TAVR) system (Medtronic, Inc., Minneapolis, Minnesota) in a single-arm, multicenter pivotal high- or extreme-risk patients with symptomatic stenosis. Although outcomes following TAVR are improving, challenges still exist. repositionable 14-F equivalent developed mitigate some these challenges. Suitable (n = 60) underwent 26- 29-mm valve....
Background: The current treatment of choice for symptomatic aortic stenosis is valve replacement (AVR) with cardiopulmonary bypass (CPB), but AVR associated significant operative morbidity and mortality in elderly patients multiple co-morbid conditions. We recently reported the first successful implantation procedure (AVI) via a mini-thoracotomy left ventricular apical puncture without bypass. now report 6-month follow-up our initial seven patients. Methods: Seven (77 ± 10 years old) were...
Abstract Objectives : We describe the technique of, and our experience with, rapid ventricular burst pacing to facilitate transcatheter heart valve implantation. Background Endovascular therapeutic procedures frequently require precise placement of implantable devices. The precision device deployment may be hampered by cardiac motion or effects intravascular flow. Burst is associated with a reduction in stroke volume, output, transvalvular flow, motion. Methods Rapid was used 40 consecutive...
BackgroundWe report the findings of SOURCE-ANZ registry clinical outcomes Edwards SAPIEN™ Transcatheter Heart Valve (THV) in Australian and New Zealand (ANZ) environment.MethodsThis single arm select patients treated eight centres, represent initial experience within ANZ with balloon expandable SAPIEN THV delivered by transfemoral (TF) transapical (TA) access.ResultsThe total enrolment for study was 132 patients, 63 TF, 56 TA, 2 were withdrawn from study. The mean ages: 83.7 81.7 (TA),...
This follow-on article (see below) comparing the differences between Edwards-Sapien valve (ESV) and Medtronic CoreValve (MCV) discusses transcatheter technologies from point of view a world-renowned team cardiac experts led by Dr Sanjeevan Pasupati Waikato Hospital, New Zealand, which has deployed both ESV MCV technology since 2008.